DDInter624 DDInter1348
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Orlistat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Multiple fractures
Multiple fractures {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Phylloquinone
Phylloquinone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Ethanolamine Oleate
Ethanolamine Oleate {u} (Compound) resembles {v} (Compound) Orlistat
Efavirenz {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Sodium Tetradecyl Sulfate
Sodium Tetradecyl Sulfate {u} (Compound) resembles {v} (Compound) Orlistat
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cholecalciferol
Cholecalciferol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orlistat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Efavirenz (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Orlistat (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Efavirenz (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Efavirenz (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Efavirenz (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Phylloquinone (Compound) and Phylloquinone may cause a minor interaction that can limit clinical effects when taken with Orlistat
Efavirenz (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Ethanolamine Oleate (Compound) and Ethanolamine Oleate (Compound) resembles Orlistat (Compound)
Efavirenz (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Sodium Tetradecyl Sulfate (Compound) and Sodium Tetradecyl Sulfate (Compound) resembles Orlistat (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cholecalciferol (Compound) and Cholecalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat